발작성 야간 혈색소뇨증(PNH) 치료제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Paroxysmal Nocturnal Hemoglobinuria Drug Market size is expected to reach USD 8.84 Billion in 2034 from USD 4.32 Billion (2025) growing at a CAGR of 8.28% during 2026-2034.

The global paroxysmal nocturnal hemoglobinuria (PNH) drug market is witnessing steady growth due to rising awareness of rare blood disorders and improved diagnostic capabilities. Increased screening and advancements in flow cytometry testing have enabled earlier detection, supporting treatment uptake. The growing availability of targeted biologic therapies has significantly improved patient survival rates and quality of life, encouraging healthcare providers to adopt advanced treatment options across developed and emerging markets.

Key growth drivers include strong research investments in complement inhibitor therapies and the expanding pipeline of novel monoclonal antibodies. Regulatory support for orphan drugs and favorable reimbursement policies in developed economies further stimulate market expansion. In addition, patient advocacy programs and improved healthcare access in emerging countries are contributing to increased diagnosis and treatment rates, strengthening overall market demand.

Looking ahead, the market is expected to benefit from next-generation therapies offering longer dosing intervals and improved safety profiles. Ongoing clinical trials focused on oral and subcutaneous formulations may enhance patient convenience and compliance. Strategic collaborations between pharmaceutical companies and research institutions are likely to accelerate innovation, while expanding healthcare infrastructure in Asia-Pacific and Latin America will create new growth opportunities over the forecast period.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• Aminoquinolines
• Monoclonal Antibodies
• Complement Inhibitors
• Immune System Modulators
• Protective Agents

By Route of Administration

• Oral
• Intravenous
• Subcutaneous
• Intramuscular

By Patient Demographics

• Age Group
• Gender
• Geographic Distribution

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Specialty Pharmacies

By Treatment Stage

• First-Line Therapy
• Second-Line Therapy
• Supportive Care
• Post-Transplant Care

COMPANIES PROFILED

• Apellis Pharmaceuticals, Alexion Pharmaceuticals Inc, Akari Therapeutics Plc, CinnaGen Co, Ra Pharmaceuticals Inc, Amgen Inc, Achillion Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc, F HoffmannLa Roche Ltd, Novartis AG, Regeneron Pharmaceuticals Inc, Biocad
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Aminoquinolines Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Monoclonal Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Complement Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Immune System Modulators Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Protective Agents Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Route Of Administration
• 5.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Intravenous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Subcutaneous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Intramuscular Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET: BY PATIENT DEMOGRAPHICS 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Patient Demographics
• 6.2. Age Group Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Gender Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Geographic Distribution Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Specialty Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET: BY TREATMENT STAGE 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Treatment Stage
• 8.2. First-Line Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Second-Line Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Supportive Care Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.5. Post-Transplant Care Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG MARKET: BY REGION 2022-2034(USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Drug Class
  • 9.2.2 By Route Of Administration
  • 9.2.3 By Patient Demographics
  • 9.2.4 By Distribution Channel
  • 9.2.5 By Treatment Stage
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Drug Class
  • 9.3.2 By Route Of Administration
  • 9.3.3 By Patient Demographics
  • 9.3.4 By Distribution Channel
  • 9.3.5 By Treatment Stage
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Drug Class
  • 9.4.2 By Route Of Administration
  • 9.4.3 By Patient Demographics
  • 9.4.4 By Distribution Channel
  • 9.4.5 By Treatment Stage
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Drug Class
  • 9.5.2 By Route Of Administration
  • 9.5.3 By Patient Demographics
  • 9.5.4 By Distribution Channel
  • 9.5.5 By Treatment Stage
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 South East Asia
  • 9.5.11 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Drug Class
  • 9.6.2 By Route Of Administration
  • 9.6.3 By Patient Demographics
  • 9.6.4 By Distribution Channel
  • 9.6.5 By Treatment Stage
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA DRUG INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 Apellis Pharmaceuticals
  • 11.2.2 Alexion Pharmaceuticals Inc
  • 11.2.3 Akari Therapeutics Plc
  • 11.2.4 CinnaGen Co
  • 11.2.5 Ra Pharmaceuticals Inc
  • 11.2.6 Amgen Inc
  • 11.2.7 Achillion Pharmaceuticals Inc
  • 11.2.8 Alnylam Pharmaceuticals Inc
  • 11.2.9 F. Hoffmann-La Roche Ltd
  • 11.2.10 Novartis AG
  • 11.2.11 Regeneron Pharmaceuticals Inc
  • 11.2.12 Biocad